Jessica Hagen
The launch comes a little over one year after digital health firm Babylon sold almost all of its U.K. assets to digital health company eMed Healthcare U.K.
According to Bloomberg, the brain-implant chipmaker raised $93 million in funding, increasing the startup's valuation to approximately $500 million.
HCA members will have access to and support for MGI's single cell and spatial omics technologies.
The guidance aims to help countries move toward healthcare digitization through a person-centered point of service system.
The company also reported Q3 2024 earnings, noting total revenue of $76.4 million, adjusted EBITDA of $7.3 million and a net loss of $14.7 million.
The acquisition includes all of NeuroReality's assets, including its flagship rehabilitation product, Koji's Quest.
The company will use the funds to expand in Asian and U.S. markets, advance its AI algorithms and grow its workforce.
The company reported a 77% YOY increase in revenue in Q3 2024 and plans to release a generic version of Novo Nordisk's GLP-1 drug on its platform in 2025.
The company offers a marketplace for individuals seeking addiction and mental health treatment. It will use the funds to scale its workforce and expand its reach.
The CRISPR therapy, HG202, was conceived using AI and machine learning and aims to treat individuals with neovascular age-related macular degeneration.